Communiqués Agentix Corp.

Actions

AGTX

US00848A1034

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:30:01 25/08/2026			Varia. 5j.	Varia. 1 janv.
0,0200 ^USD	0,00%		0,00%	-46,67%

10/08	Agentix Corp. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
01/07	Agentix Corp. publie ses résultats pour l'exercice clos le 31 mars 2026	CI

Communiqués

10/08	Agentix : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
01/07	Agentix : Annual Report for Fiscal Year Ending 03-31, 2026 (Form 10-K)	PU
14/02/23	AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
14/11/22	AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
11/08/22	AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
18/07/22	AGENTIX CORP. - 10-KT - Management's Discussion and Analysis Of Financial Condition and Results of Operations.	AQ
14/06/22	AGENTIX CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
13/04/22	AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
17/02/22	Happening Today: Agentix Corp. Presenting At The Emerging Growth Conference At 10:30am EST; Highlighting Clinical-Stage Developments and 2022 Initiatives	AQ
14/02/22	Agentix Corp. to Present at the Emerging Growth Conference on February 16, 2022 at 10:30am EST; Highlighting Clinical-Stage Developments and 2022 Initiatives	AQ
13/01/22	AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
04/01/22	AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast	NE
21/12/21	AGENTIX CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
07/10/21	AGENTIX : Management's Discussion and Analysis Of Financial Condition and Results of Operations. (form 10-K)	AQ
09/09/21	AGENTIX Corp. Stock Surges 27% On NHRI Licensing Deal To Treat Obesity and Type 2 Diabetes (OTC Pink: AGTX)	AQ
16/07/21	AGENTIX CORP. : Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)	AQ
14/07/21	AGENTIX CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
09/07/21	AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
04/06/21	AGENTIX CORP. : Change in Directors or Principal Officers (form 8-K)	AQ
02/06/21	Agentix Corp :. (AGTX) Signs Deal With NHRI To License CBD-Based Compound To Treat Type 2 Diabetes; Adds Catalyst To Back Half Of 2021	AQ
27/05/21	AGENTIX CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
29/03/21	AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
13/01/21	AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/12/20	AGENTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
11/11/20	Agentix Biopharma CEO, Rudy Mazzocchi, Discusses the Company's Growth Strategy with The Stock Day Podcast	NE